Blood test to guide extra treatment after lung radiation
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study uses a special blood test that looks for cancer DNA to decide whether patients with early lung cancer should get additional (adjuvant) therapy after SBRT radiation. It may help avoid unnecessary treatment or catch those who could benefit from it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage non-small cell lung cancer confirmed by pathology (not small cell).
- You’re 18–80 years old, and your doctor expects you’ll live more than 3 months.
- Recent blood tests are adequate (enough hemoglobin, neutrophils, and platelets).
- Recent liver and kidney tests are within required limits.
- You can take any study medications as required (able to swallow; no severe diarrhea or blockage).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a single, very high-dose focused radiation treatment can control early-stage lung cancer. It may help people who can’t or prefer not to have surgery, by delivering precise radiation to the tumor while aiming to spare nearby tissue.
This study looks at changes in small molecules, genetic material, and other markers in the blood before and after lung cancer surgery. The goal is to develop a simple blood test to monitor patients over time and see if the cancer comes back.
This trial tests a personalized radiation treatment called SBRT for early-stage non-small cell lung cancer that is located in the outer part of the lung and cannot be removed with surgery. The goal is to see if this approach works well for people who cannot have surgery or choose not to.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with stereotactic body radiation therapy (SBRT) for people with early-stage non-small cell lung cancer. The goal is to see if this treatment can help shrink or control the cancer before surgery.
This trial tests a more precise radiation technique (stereotactic body radiotherapy) for early-stage lung cancer or small lung tumors. It aims to reduce side effects by eliminating the usual safety margin around the tumor.
This trial tests adding targeted radiation before standard immunotherapy and chemotherapy for people with stage 2-3 non-small cell lung cancer that can be surgically removed. The goal is to see if the radiation helps shrink the tumor more before surgery.
Hear when a new Stereotactic Body Radiation Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.